Last reviewed · How we verify
Topical Corticosteroid (TCS)
Topical Corticosteroid (TCS) is a Topical corticosteroid Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Eczema, Psoriasis, Dermatitis.
Topical corticosteroids reduce inflammation by suppressing the immune system's response to perceived threats.
Topical corticosteroids (TCS) are used to treat conditions such as atopic dermatitis, neurodermatitis, and dermatitis. They are small molecule compounds that work to alleviate symptoms of these conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Eli Lilly and Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Topical Corticosteroid (TCS) |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Topical corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
They do this by inhibiting the production of pro-inflammatory cytokines and other mediators of inflammation, thereby reducing the severity of symptoms associated with conditions such as eczema, psoriasis, and dermatitis.
Approved indications
- Eczema
- Psoriasis
- Dermatitis
Common side effects
- Skin atrophy
- Hypopigmentation
- Allergic contact dermatitis
Key clinical trials
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (PHASE3)
- Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (PHASE3)
- A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (PHASE3)
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (PHASE3)
- A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical Corticosteroid (TCS) CI brief — competitive landscape report
- Topical Corticosteroid (TCS) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Topical Corticosteroid (TCS)
What is Topical Corticosteroid (TCS)?
How does Topical Corticosteroid (TCS) work?
What is Topical Corticosteroid (TCS) used for?
Who makes Topical Corticosteroid (TCS)?
What drug class is Topical Corticosteroid (TCS) in?
What development phase is Topical Corticosteroid (TCS) in?
What are the side effects of Topical Corticosteroid (TCS)?
Related
- Drug class: All Topical corticosteroid drugs
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Eczema
- Indication: Drugs for Psoriasis
- Indication: Drugs for Dermatitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing